<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894554</url>
  </required_header>
  <id_info>
    <org_study_id>201310070MINA</org_study_id>
    <nct_id>NCT02894554</nct_id>
  </id_info>
  <brief_title>Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.</brief_title>
  <official_title>A Single-Center, Open-Label Study to Evaluate the Renal Function Improvement in Lamivudine Long Term Used HBsAg Positive Kidney Transplantation Patients After Switch to Telbivudine Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hepatitis B virus (HBV) infection rate among renal transplant recipients was reported&#xD;
      from 3% to 20.9%. And patient survival and graft survival rates following renal&#xD;
      transplantation may be worsen in HBsAg-positive carriers than in HBsAg-negative recipients.&#xD;
      Due to viral replication in asymptomatic HBV carriers induced by post-transplant&#xD;
      immunosuppression, liver-related complications, such as liver failure and bleeding, account&#xD;
      for 37% to 57% of the mortality cases in HBsAg-positive renal allograft recipients.&#xD;
&#xD;
      Since the late 1990s, Lamivudine has been recognized as an effective and well-tolerated&#xD;
      antiviral drug for chronic HBV infection. Lamivudine treatment among HBsAg-positive renal&#xD;
      allograft recipients has significantly improved patient survival rates during short-term&#xD;
      follow-up. Telbivudine is another approved nucleoside antiviral agent for patients with&#xD;
      chronic hepatitis B (CHB). Recently, it was shown that eGFR was improved in HBV-related&#xD;
      decompensated cirrhosis patients after 52 weeks Telbivudine treatments. Additional eGFR&#xD;
      increase was also observed in Lamivudine experienced CHB patients after switch to Telbivudine&#xD;
      treatment.&#xD;
&#xD;
      However, limited results were known about the renal function affected by oral anti-HBV drugs&#xD;
      when patients received kidney transplantation. Therefore, we would like to conduct this study&#xD;
      to evaluate the renal function of Lamivudine long term used HBsAg positive patients received&#xD;
      kidney transplantation after switch to Telbivudine treatment. The clinical and virological&#xD;
      outcomes will provide valuable insights of clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    clinical myalgia&#xD;
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the renal function in HBsAg positive kidney transplant patients in Telbivudine and Lamivudine treatment groups by eGFR at 48 Weeks after treatment using MDRD formula.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HBsAg-positive Renal Allograft Recipients</condition>
  <arm_group>
    <arm_group_label>lamivudine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HBsAg (+) patients received renal transplant and under lamivudine therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>telbivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <arm_group_label>telbivudine</arm_group_label>
    <other_name>Sebivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <arm_group_label>lamivudine</arm_group_label>
    <other_name>Zeffix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Kidney transplant patients who are treated with Lamivudine over 6 months (Considering&#xD;
             include post kidney transplantation &gt; 6 months with stable calcineurin inhibitors&#xD;
             level&#xD;
&#xD;
          2. Seropositive of HBsAg for 6 months&#xD;
&#xD;
          3. Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hepatitis cirrhosis patients&#xD;
&#xD;
          2. Co-infection with hepatitis C virus or HIV&#xD;
&#xD;
          3. Pregnant or nursing&#xD;
&#xD;
          4. YMDD resistant at baseline&#xD;
&#xD;
          5. ABO incompatible renal transplantation&#xD;
&#xD;
          6. Cross match positive&#xD;
&#xD;
          7. Poor renal function at baseline (eGFR&lt;20)&#xD;
&#xD;
          8. Known hypersensitivity or intolerance to any of the ingredients in Telbivudine&#xD;
&#xD;
          9. Known history of Telbivudine resistance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

